ReviewNature reviews. Gastroenterology & hepatology2011
Optimization of conventional therapy in patients with IBD.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Multi-modal therapeutic approaches to inflammatory bowel disease: plant-derived compounds, nanoparticle drug delivery systems, and gene-based interventions.Molecular biology reports · 2026Review
- Rectal nanoparticulate-hydrogel delivering budesonide to reduce enterohepatic drug metabolism and clearance.Drug delivery and translational research · 2026Article
- Colon-targeted oral delivery of melatonin for regulating macrophage activity and intestinal barrier in ulcerative colitis.Theranostics · 2026Article
- An oral engineered cerium-peptide composite microsphere inhibits inflammatory bowel disease and reverses chronic fibrosis.Journal of nanobiotechnology · 2025Article
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.Intestinal research · 2025Review
- Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and its fibrotic complication.Nature communications · 2024Article
- Saffron as a Promising Therapy for Inflammatory Bowel Disease.Nutrients · 2024Review
- Chicoric Acid Effectively Mitigated Dextran Sulfate Sodium (DSS)-Induced Colitis in BALB/c Mice by Modulating the Gut Microbiota and Fecal Metabolites.International journal of molecular sciences · 2024Article
- Colon-Targeted Trans-Cinnamic Acid Ameliorates Rat Colitis by Activating GPR109A.Pharmaceutics · 2022Article
- Bioadhesive Tannic-Acid-Functionalized Zein Coating Achieves Engineered Colonic Delivery of IBD Therapeutics via Reservoir Microdevices.Pharmaceutics · 2022Article
- Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional Agents.Crohn's & colitis 360 · 2022Article
- Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.World journal of clinical cases · 2022Review
- A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease.Science advances · 2022Article
- Beneficial role of Pistacia lentiscus aqueous extract in experimental colitis: anti-inflammatory and potential therapeutic effects.Inflammopharmacology · 2021Article
- Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease.Journal of inflammation research · 2021Review
- Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide.Journal of molecular medicine (Berlin, Germany) · 2020Article
- An In Situ Gelling System for the Local Treatment of Inflammatory Bowel Disease (IBD). The Loading of Maqui (Pharmaceutics · 2019Article
- Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.Alimentary pharmacology & therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of patients with IBD use conventional therapy (namely, aminosalicylates, antibiotics, corticosteroids and immunomodulatory agents) for prolonged periods of time, to both induce and maintain remission. Treatment paradigms in IBD have evolved towards a rapid escalation of therapy to achieve stringent goals, including mucosal healing and a reduction in the need for hospital admission and surgery. In this context, the failure to optimize conventional therapy can lead to a potentially effective treatment being abandoned too early, which is undesirable when only a limited number of drugs are effective in the management of IBD, and could also lead to patients being unnecessarily exposed to potentially toxic and/or expensive biologic drugs. This Review provides an overview of the many ways in which conventional therapy can be optimized, and describes strategies to improve adherence to drug regimens, such as simplifying the dosing regimen, optimizing drug delivery and dose, and tailoring medication on the basis of metabolite levels.
Indexed as
Identifiers
21970871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.